This study is a randomised, double blinded, community-based clinical trial and will be undertaken in primary care sites across Victoria, New South Wales and Queensland, Australia. Following a 4-week active run-in period, eligible participants will be randomised to either dapagliflozin 10mg daily, or metformin XR 2000mg daily in a 1:1 ratio.
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with recently diagnosed Type 2 Diabetes.